Sickle Cell Anemia Therapeutics Market Industry Outlook By Drivers, Restraints And 2017-2025
Drastic reduction in total number of RBC count is called as anemia, which can be defined as the incapability to transport optimum oxygen by various blood cells. This disease inherits various types of genetical blood disorders.
Most common type of sickle cell disease is the sickle cell anemia. This disorder gives rise to a specific hemoglobin irregularity, particularly in the protein which transfers oxygen in the blood. This health disorder might lead to several health problems including microbial infections, pain attacks are known as sickle cell crisis, swelling in the limbs, and in most cases, it may cause a stroke.
Request To Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10220963
According to the WHO, nearly 5% of the global population can get affected by the sickle cell anemia disease. In some regions, this percentage is nearer to 25%. WHO estimates derived that the sickle cell disease occurrences can be highest in the Africa region. In order to meet this high disease prevalence, WHO has taken several initiatives to reduce these incidences.
Moreover, according to PLOS Medicine, occurrences of sickle cell anemia disease will likely rise by 30% by the end of 2050, particularly in sub-Saharan Africa. Due to these factors, there will be a significant rise in demand for treatment, which will eventually drive the global sickle cell anemia therapeutics market over the forecast period.
Moreover, there are several new technologies, which are under development for treating this disease, such as gene therapy, bone marrow transplantation, which will further open new opportunity ventures for the growth of global sickle cell anemia therapeutics market over the projected period.
Lack of treatment facilities, coupled with under-developed health care infrastructure in the Africa region might show a negative impact on the growth of global sickle cell anemia therapeutics market over the projected period.
Based on medication, the global sickle cell anemia therapeutics market has been segmented into pain-relieving medications, hydroxyurea, anti-biotics, chronic cell transfusion, stem cell transplantation, and other medications such as antimetabolites, analgesics, vaccines, and folic acids. Hydroxyurea will witness high preference for the treatment of sickle cell anemia, owing to the drug’s safety, coupled with lower treatment costs.
North America sickle cell anemia therapeutics market is expected to dominate the global market over the projected period. According to the Centers for Disease Control and Prevention, more than 100,000 people in the U.S. alone were affected by this disease in 2016. Rise in disease incidences among the Americans, will significantly drive the demand for prevention and cure of sickle cell anemia disorder, which will further fuel the regional market growth over the projected period.
Africa sickle cell anemia therapeutics market is anticipated to hold the prime market share over the forecast period, owing to the increasing number of sickle cell diseases cases in the African region. Asia Pacific sickle cell anemia therapeutics market is expected to be driven by the adoption of new healthcare techniques for the treatment of this disease. Moreover, growing awareness among the population of India and China about this disease will further create a large opportunity venture for the key market players in the Asia Pacific.
Read More:- https://www.kennethresearch.com/report-details/sickle-cell-anemia-therapeutics-market/10220963
Some of the prominent players in the global sickle cell anemia therapeutics market include Baxter, Bristol-Myers Squibb, Modus Therapeutics AB, Bluebird Bio, Daiichi Sankyo, GlycoMimetics, Eli Lilly and Company, HemaQuest Pharmaceuticals, Emmaus Medical, Merck Sharp & Dohme, Mast Therapeutics, Selexys Pharmaceuticals, and Pfizer among several others.
To improve the treatment facilities, various key players are providing their support to other players in the form of investments. For instance, in July 2018, HealthCap invested US$ 6.63 million in Modus Therapeutics AB. This investment will help Modus Therapeutics AB to complete their phase 2 trials with sevuparin among patients suffering from sickle cell disease
Email : Sales@kennethresearch.com
Phone: +1 313 462 0609
About Kenneth Research:-
Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sickle Cell Anemia Therapeutics Market Industry Outlook By Drivers, Restraints And 2017-2025 here
News-ID: 1896745 • Views: 354
More Releases from Kenneth Research
Photomask Market Growth Analysis by Revenue, Size, Share, Scenario on Latest Tre …
Kenneth Research provides an extensive study by our analysts which offers forecast assessment by correlating the historical data with key market dynamics. The Photomask Market further includes trends and opportunities that are highlighted, along with the market valuation. The market is segmented by segments and portrays the industry overview along with elaborate description of the market for the forecast period 2020-2025. The report also constitutes future growth statistics which is
Embedded Systems Market 2020 New Innovations Trends, Research, Global Share and …
Kenneth Research provides an extensive study by our analysts which offers forecast assessment by correlating the historical data with key market dynamics. The Embedded Systems Market further includes trends and opportunities that are highlighted, along with the market valuation. The market is segmented by segments and portrays the industry overview along with elaborate description of the market for the forecast period 2020-2025. The report also constitutes future growth statistics which
DNS Service Market : Industry Development Scenario and Forecast to 2025
Global DNS Service Market to reach USD 600 million by 2025.Global DNS Service Market valued approximately USD 230 million in 2016 is anticipated to grow with a healthy growth rate of more than 12% over the forecast period 2018-2025. The DNS Service Market is continuously growing across the world over the coming years. The major driving factor of global DNS Service market are increasing awareness to safeguard the websites from
Xenon Lights Market Growth, Size, Share, Demand, Trends and Manufacturers Analys …
Kenneth Research provides an extensive study by our analysts which offers forecast assessment by correlating the historical data with key market dynamics. The Xenon Lights Market further includes trends and opportunities that are highlighted, along with the market valuation. The market is segmented by segments and portrays the industry overview along with elaborate description of the market for the forecast period 2020-2025. The report also constitutes future growth statistics which
More Releases for Therapeutics
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics
SMi are delighted to welcome Oliver Rausch, VP Research & Development, Storm Therapeutics, onto the speaker line-up for day 1 at RNA Therapeutics 2018! Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series; an investment that launched STORM
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other